http://orcid.org/0000-0003-0515-9128
Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Fatima S. Mehdhar, Ebrahim Abdel-Galil, Ali Saeed, Ehab Abdel-Latif & Ghada E. Abd El Ghani. (2023) Synthesis of New Substituted Thiophene Derivatives and Evaluating their Antibacterial and Antioxidant Activities. Polycyclic Aromatic Compounds 43:5, pages 4496-4511.
Read now
Read now
Ronald J. Overmars, Zoë Krullaars & Thibault Mesplède. (2023) Investigational drugs for HIV: trends, opportunities and key players. Expert Opinion on Investigational Drugs 32:2, pages 127-139.
Read now
Read now
Santiago Grau, Jose Maria Miró, Julian Olalla, Juan C Alcalá, Antonio Castro, Dario Rubio-Rodríguez & Carlos Rubio-Terrés. (2023) Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature. Expert Review of Anti-infective Therapy 21:1, pages 65-76.
Read now
Read now
Arturo Ciccullo, Gianmaria Baldin, Cristina Putaggio, Simona Di Giambenedetto & Alberto Borghetti. (2021) Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV. Expert Opinion on Drug Safety 20:11, pages 1317-1332.
Read now
Read now
Articles from other publishers (11)
Monica Basso, Giuliana Battagin, Stefano Nicolè, Maria Cristina Rossi, Francesco Colombo, Nicole Pirola, Stefano Baratti, Silvia Storato, Federico Giovagnorio, Vincenzo Malagnino, Grazia Alessio, Antonio Vinci, Massimo Maurici, Loredana Sarmati & Saverio Giuseppe Parisi. (2023) Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study. Viruses 15:8, pages 1727.
Crossref
Crossref
Meng A. Xiao, Jenna Cleyle, Sunbin Yoo, Mekayla Forrest, Zoë Krullaars, Hanh Thi Pham & Thibault Mesplède. (2023) The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration. Antimicrobial Agents and Chemotherapy 67:5.
Crossref
Crossref
Emma G. Foster, Howard E. Gendelman & Aditya N. Bade. (2022) HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment. Pharmaceuticals 15:12, pages 1533.
Crossref
Crossref
Jeroen J.A. van Kampen, Hanh Thi Pham, Sunbin Yoo, Ronald J. Overmars, Cynthia Lungu, Rizwan Mahmud, Carolina A.M. Schurink, Sander van Boheemen, Rob A. Gruters, Pieter L.A. Fraaij, David M. Burger, Jolanda J.C. Voermans, Casper Rokx, David A.M.C. van de Vijver & Thibault Mesplède. (2022) HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report. Journal of Global Antimicrobial Resistance 31, pages 323-327.
Crossref
Crossref
Rafael Micán, Alejandro de Gea Grela, Julen Cadiñanos, Rosa de Miguel, Carmen Busca, Jose I. Bernardino, Eulalia Valencia, Maria Luisa Montes, Rocío Montejano, Victoria Moreno, Ignacio Pérez Valero, Lucía Serrano, Juan González-García, Jose R. Arribas & Luz Martín-Carbonero. (2022) Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients. AIDS 36:14, pages 1941-1947.
Crossref
Crossref
Vera E. Bukkems, Carmen Hidalgo-Tenorio, Coral Garcia, Astrid G.W. van Hulzen, Olivier Richel, David M. Burger & Angela P. Colbers. (2021) First pharmacokinetic data of bictegravir in pregnant women living with HIV. AIDS 35:14, pages 2405-2406.
Crossref
Crossref
Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove, Juan Berenguer, Michelle L. D’Antoni, Christiana Blair, Susan K. Chuck, David Piontkowsky, Hal Martin, Richard Haubrich, Ian R. McNicholl & Joel Gallant. (2021) Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial. Infectious Diseases and Therapy 10:2, pages 775-788.
Crossref
Crossref
Hanh T Pham, Brunna M Alves, Sunbin Yoo, Meng A Xiao, Jing Leng, Peter K Quashie, Esmeralda A Soares, Jean-Pierre Routy, Marcelo A Soares & Thibault Mesplède. (2021) Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir. Journal of Antimicrobial Chemotherapy 76:3, pages 639-647.
Crossref
Crossref
Sara H. Bares & Susan Swindells. (2020) Latent Tuberculosis and HIV Infection. Current Infectious Disease Reports 22:7.
Crossref
Crossref
Agnieszka Kolakowska, Anaenza Freire Maresca, Intira Jeannie Collins & Johann Cailhol. (2019) Update on Adverse Effects of HIV Integrase Inhibitors. Current Treatment Options in Infectious Diseases 11:4, pages 372-387.
Crossref
Crossref
Haibo Mei, Jianlin Han, Santos Fustero, Mercedes Medio‐Simon, Daniel M. Sedgwick, Claudio Santi, Renzo Ruzziconi & Vadim A. Soloshonok. (2019) Fluorine‐Containing Drugs Approved by the FDA in 2018. Chemistry – A European Journal 25:51, pages 11797-11819.
Crossref
Crossref